A pharmacist's perspective on health and metabolic disease
I’ve just been asked about PCSK9 inhibitors. These “Pesky” medications, which include the agents Alirocumab and Evolocumab, lower LDL cholesterol by inactivating a protein in the liver called called proprotein … Continue reading →
Enter your email address to follow this blog and receive notifications of new posts by email.
Join 808 other followers
Create a free website or blog at WordPress.com.